Richard G B Langley - JoVE Visualize

Showing results (11-20 of 23) with videos related to

Pageof 3

Sort By:

Academic Medicine : Journal of the Association of American Medical Colleges|June 25, 2009

Temporary tattoos to simulate skin disease: report and validation of a novel teaching toolRichard G B Langley, Susan A Tyler, Amy E Ornstein, et al.

Pediatric Dermatology|June 26, 2008

Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitisRichard G B Langley, Lawrence F Eichenfield, Anne W Lucky, et al.

The Breast Journal|November 22, 2005

Erdheim-Chester disease of the breast: a case report and review of the literaturePenny J Barnes, Annette Foyle, Kelly A Dakin Haché, et al.

Dermatology (Basel, Switzerland)|October 4, 2007

The diagnostic accuracy of in vivo confocal scanning laser microscopy compared to dermoscopy of benign and malignant melanocytic lesions: a prospective studyRichard G B Langley, Noreen Walsh, Ashley E Sutherland, et al.

Journal of the American Academy of Dermatology|March 22, 2002

Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescentsLawrence F Eichenfield, Anne W Lucky, Mark Boguniewicz, et al.

Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|November 4, 2006

Clinical Experience Acquired with Raptiva (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from extended treatment in an international, Phase III, placebo-controlled trialWolfram Sterry, Georg Stingl, Richard G B Langley, et al.

Clinical Therapeutics|November 18, 2005

Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experienceRichard G B Langley, Wayne P Carey, Elyse S Rafal, et al.

International Journal of Dermatology|January 25, 2005

Use of pimecrolimus cream 1% (Elidel) in the treatment of atopic dermatitis in infants and children: the effects of ethnic origin and baseline disease severity on treatment outcomeLawrence F Eichenfield, Anne W Lucky, Richard G B Langley, et al.

Dermatology (Basel, Switzerland)|October 13, 2006

A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasisCraig L Leonardi, Darryl Toth, Jennifer C Cather, et al.

Journal of the American Academy of Dermatology|June 20, 2015

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)Kim Papp, Kristian Reich, Craig L Leonardi, et al.

Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:

Pageof 3

Academic Medicine : Journal of the Association of American Medical Colleges|June 25, 2009

Temporary tattoos to simulate skin disease: report and validation of a novel teaching toolRichard G B Langley, Susan A Tyler, Amy E Ornstein, et al.

Pediatric Dermatology|June 26, 2008

Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitisRichard G B Langley, Lawrence F Eichenfield, Anne W Lucky, et al.

The Breast Journal|November 22, 2005

Erdheim-Chester disease of the breast: a case report and review of the literaturePenny J Barnes, Annette Foyle, Kelly A Dakin Haché, et al.

Dermatology (Basel, Switzerland)|October 4, 2007

The diagnostic accuracy of in vivo confocal scanning laser microscopy compared to dermoscopy of benign and malignant melanocytic lesions: a prospective studyRichard G B Langley, Noreen Walsh, Ashley E Sutherland, et al.

Journal of the American Academy of Dermatology|March 22, 2002

Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescentsLawrence F Eichenfield, Anne W Lucky, Mark Boguniewicz, et al.

Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|November 4, 2006

Clinical Experience Acquired with Raptiva (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from extended treatment in an international, Phase III, placebo-controlled trialWolfram Sterry, Georg Stingl, Richard G B Langley, et al.

Clinical Therapeutics|November 18, 2005

Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experienceRichard G B Langley, Wayne P Carey, Elyse S Rafal, et al.

International Journal of Dermatology|January 25, 2005

Use of pimecrolimus cream 1% (Elidel) in the treatment of atopic dermatitis in infants and children: the effects of ethnic origin and baseline disease severity on treatment outcomeLawrence F Eichenfield, Anne W Lucky, Richard G B Langley, et al.

Dermatology (Basel, Switzerland)|October 13, 2006

A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasisCraig L Leonardi, Darryl Toth, Jennifer C Cather, et al.

Journal of the American Academy of Dermatology|June 20, 2015

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)Kim Papp, Kristian Reich, Craig L Leonardi, et al.

Pageof 3